Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies (Details Narrative)

v3.26.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 05, 2025
Aug. 22, 2025
Nov. 30, 2025
Dec. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Aug. 31, 2025
Jan. 29, 2021
AccountingPoliciesLineItems [Line Items]                
Cash equivalents       $ 0 $ 0 $ 0    
Cash balances       358,975 358,975 13,199    
Revenue       $ 6,000 $ 6,000    
Fair value of investment cost       26,573 26,573      
Marketable securities       $ 38,531 $ 38,531 82,376    
Shares issued price, per share       $ 1.45 $ 1.45      
Unrealized loss on investment         $ 43,845      
Investments information         Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock      
Advertising, marketing, and promotion expense         $ 0 4,969    
Depreciation         0 0    
Stock-based compensation expense         12,700,399    
Share Price $ 0.25              
Derivative Liability, Current       $ 1,944,806 1,944,806    
Gain (Loss) on Derivative Instruments, Net, Pretax         (3,425,796)    
Investment fair value           0    
Unrealized loss         0 0    
Marketable securities       38,531 $ 38,531 $ 82,376    
Weighted average number of common shares         25,723,927 21,674,000    
Convertible Notes Payable [Member]                
AccountingPoliciesLineItems [Line Items]                
Antidilutive securities excluded from computation of earnings per share, amount         50,000 4,218,372    
Pharmacy No, 27, Ltd [Member]                
AccountingPoliciesLineItems [Line Items]                
Ownership Percentage               20.00%
CEO Employment Agreement [Member]                
AccountingPoliciesLineItems [Line Items]                
Stock-based compensation expense   $ 2,184,739            
Number of shares issued 16,667,788       6,823,847      
Derivative Liability, Current   $ 3,425,796   $ 1,944,806 $ 1,944,806   $ 3,425,796  
Gain (Loss) on Derivative Instruments, Net, Pretax         1,480,990      
Mr. Campbells Employment Agreement [Member]                
AccountingPoliciesLineItems [Line Items]                
Stock-based compensation expense         $ 1,423,079      
Share Price     $ 1.57          
Number of shares issued     906,420   1,686,684      
Chief Executive Officer [Member]                
AccountingPoliciesLineItems [Line Items]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross         780,264      
Share Price       $ 2.80 $ 2.80      
Furniture and Fixtures [Member] | Minimum [Member]                
AccountingPoliciesLineItems [Line Items]                
Useful life       3 years 3 years      
Furniture and Fixtures [Member] | Maximum [Member]                
AccountingPoliciesLineItems [Line Items]                
Useful life       5 years 5 years